PROTECTION AMI
- 1,058 participants
- 5 sites in New Zealand
- 18 participating countries
Inhibition of δ-PROTEin kinase C for the reducTION of infarct size in Acute Myocardial Infarction
Phase IIb clinical trial investigating whether the new drug KAI-9803 can reduce damage to the heart muscle, in people who have a serious heart attack, known as an ST elevation myocardial infarction (STEMI).